{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T02:58:12Z","timestamp":1785466692071,"version":"3.56.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmol Ther"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s40123-026-01453-7","type":"journal-article","created":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T15:17:30Z","timestamp":1783351050000},"page":"2813-2824","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-Life 1-Year Results and Predictors of Visual Outcome with Intravitreal Faricimab for Treatment of Exudative Neovascular Age-Related Macular Degeneration"],"prefix":"10.1007","volume":"15","author":[{"given":"Federico","family":"Beretta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Scalabrin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edoardo","family":"Balduzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Puligheddu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Bandello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Sacconi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3292-9581","authenticated-orcid":false,"given":"Giuseppe","family":"Querques","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,6]]},"reference":[{"issue":"2","key":"1453_CR1","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1001\/jama.2023.26074","volume":"331","author":"M Fleckenstein","year":"2024","unstructured":"Fleckenstein M, Schmitz-Valckenberg S, Chakravarthy U. Age-related macular degeneration: a review. JAMA Am Med Assoc. 2024;331(2):147\u201357. https:\/\/doi.org\/10.1001\/jama.2023.26074.","journal-title":"JAMA Am Med Assoc"},{"issue":"10326","key":"1453_CR2","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/S0140-6736(22)00010-1","volume":"399","author":"JS Heier","year":"2022","unstructured":"Heier JS, Khanani AM, Quezada Ruiz C, et\u00a0al. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet. 2022;399(10326):729\u201340. https:\/\/doi.org\/10.1016\/S0140-6736(22)00010-1.","journal-title":"Lancet"},{"key":"1453_CR3","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.2147\/OPTH.S424315","volume":"17","author":"RB Rush","year":"2023","unstructured":"Rush RB. One-year outcomes of faricimab treatment for aflibercept-resistant neovascular age-related macular degeneration. Clin Ophthalmol. 2023;17:2201\u20138. https:\/\/doi.org\/10.2147\/OPTH.S424315.","journal-title":"Clin Ophthalmol"},{"issue":"7","key":"1453_CR4","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1038\/s41433-025-03616-5","volume":"39","author":"IK Janmohamed","year":"2025","unstructured":"Janmohamed IK, Mushtaq A, Kabbani J, et\u00a0al. 1-year real-world outcomes of faricimab in previously treated neovascular age-related macular degeneration. Eye (Lond). 2025;39(7):1344\u20138. https:\/\/doi.org\/10.1038\/s41433-025-03616-5.","journal-title":"Eye (Lond)"},{"key":"1453_CR5","doi-asserted-by":"publisher","first-page":"470","DOI":"10.3390\/pharmaceutics","volume":"16","author":"W Aljundi","year":"2024","unstructured":"Aljundi W, Daas L, Suffo S, Seitz B, Abdin AD. First-year real-life experience with intravitreal faricimab for refractory neovascular age-related macular degeneration. Pharmaceutics. 2024;16:470. https:\/\/doi.org\/10.3390\/pharmaceutics.","journal-title":"Pharmaceutics"},{"issue":"11","key":"1453_CR6","doi-asserted-by":"publisher","first-page":"2985","DOI":"10.1007\/s40123-024-01036-4","volume":"13","author":"G Cancian","year":"2024","unstructured":"Cancian G, Paris A, Agliati L, et\u00a0al. One-year real-world outcomes of intravitreal faricimab for previously treated neovascular age-related macular degeneration. Ophthalmol Ther. 2024;13(11):2985\u201397. https:\/\/doi.org\/10.1007\/s40123-024-01036-4.","journal-title":"Ophthalmol Ther"},{"issue":"5","key":"1453_CR7","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1177\/24741264251352888","volume":"9","author":"K Okawa","year":"2025","unstructured":"Okawa K, Maruyama-Inoue M, Chin JY, Inoue T, Yanagi Y, Kadonosono K. One-year outcomes of intravitreal faricimab injection in treatment-na\u00efve patients with neovascular age-related macular degeneration. J Vitreoretin Dis. 2025;9(5):632\u20138. https:\/\/doi.org\/10.1177\/24741264251352888.","journal-title":"J Vitreoretin Dis"},{"key":"1453_CR8","doi-asserted-by":"publisher","DOI":"10.1007\/s10792-025-03717-w","author":"A Scampoli","year":"2025","unstructured":"Scampoli A, Carl\u00e0 MM, Grieco G, et\u00a0al. One-year outcomes of faricimab for neovascular age related macular degeneration with OCT angiography: focus on resistant and refractory cases. Int Ophthalmol. 2025. https:\/\/doi.org\/10.1007\/s10792-025-03717-w.","journal-title":"Int Ophthalmol"},{"key":"1453_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-59894-8","author":"H Takahashi","year":"2024","unstructured":"Takahashi H, Inoda S, Takahashi H, et\u00a0al. One-year visual and anatomical outcomes of intravitreal faricimab injection for neovascular age-related macular degeneration after prior brolucizumab treatment. Sci Rep. 2024. https:\/\/doi.org\/10.1038\/s41598-024-59894-8.","journal-title":"Sci Rep"},{"issue":"8","key":"1453_CR10","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1007\/s00417-025-06849-y","volume":"263","author":"A Scampoli","year":"2025","unstructured":"Scampoli A, Carl\u00e0 MM, Grieco G, et\u00a0al. One-year functional and structural results of faricimab for treatment-na\u00efve neovascular age related macular degeneration: an OCT angiography study. Graefes Arch Clin Exp Ophthalmol. 2025;263(8):2219\u201326. https:\/\/doi.org\/10.1007\/s00417-025-06849-y.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"2","key":"1453_CR11","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s10384-023-01040-4","volume":"68","author":"H Matsumoto","year":"2024","unstructured":"Matsumoto H, Hoshino J, Nakamura K, Akiyama H. One-year results of treat-and-extend regimen with intravitreal faricimab for treatment-na\u00efve neovascular age-related macular degeneration. Jpn J Ophthalmol. 2024;68(2):83\u201390. https:\/\/doi.org\/10.1007\/s10384-023-01040-4.","journal-title":"Jpn J Ophthalmol"},{"key":"1453_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-62559-1","author":"R Mukai","year":"2024","unstructured":"Mukai R, Kataoka K, Tanaka K, et\u00a0al. One-year outcomes and safety assessment of faricimab in treatment-na\u00efve patients with neovascular age-related macular degeneration in Japan. Sci Rep. 2024. https:\/\/doi.org\/10.1038\/s41598-024-62559-1.","journal-title":"Sci Rep"},{"issue":"4","key":"1453_CR13","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1038\/s41433-024-03487-2","volume":"39","author":"A Patwardhan","year":"2025","unstructured":"Patwardhan A, Ali N, Law S. Intravitreal faricimab in treatment-na\u00efve neovascular age-related macular degeneration: real-world outcome of 12-week extension after the loading dose from a UK centre. Eye (Basingstoke). 2025;39(4):766\u201370. https:\/\/doi.org\/10.1038\/s41433-024-03487-2.","journal-title":"Eye (Basingstoke)"},{"issue":"9","key":"1453_CR14","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1016\/j.oret.2025.03.015","volume":"9","author":"G Grimaldi","year":"2025","unstructured":"Grimaldi G, Ambresin A, Pfister IB, et\u00a0al. One-year outcomes after switching to faricimab in eyes with pretreated neovascular age-related macular degeneration: a swiss Retina Research Network report. Ophthalmol Retina. 2025;9(9):838\u201347. https:\/\/doi.org\/10.1016\/j.oret.2025.03.015.","journal-title":"Ophthalmol Retina"},{"issue":"5","key":"1453_CR15","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.ophtha.2019.11.004","volume":"127","author":"RF Spaide","year":"2020","unstructured":"Spaide RF, Jaffe GJ, Sarraf D, et\u00a0al. Consensus nomenclature for reporting neovascular age-related macular degeneration data: consensus on Neovascular Age-Related Macular Degeneration Nomenclature Study Group. Ophthalmology. 2020;127(5):616\u201336. https:\/\/doi.org\/10.1016\/j.ophtha.2019.11.004. (Epub 2019 Nov 14. Erratum in: Ophthalmology. 2020 Oct;127(10):1434-1435. 10.1016\/j.ophtha.2020.07.019).","journal-title":"Ophthalmology"},{"issue":"7","key":"1453_CR16","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1136\/bjophthalmol-2019-314625","volume":"104","author":"K Romdhane","year":"2020","unstructured":"Romdhane K, Zola M, Matet A, et\u00a0al. Predictors of treatment response to intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy for choroidal neovascularisation secondary to chronic central serous chorioretinopathy. Br J Ophthalmol. 2020;104(7):910\u20136.","journal-title":"Br J Ophthalmol"},{"issue":"8","key":"1453_CR17","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1038\/s41433-023-02918-w","volume":"38","author":"AE Sepetis","year":"2024","unstructured":"Sepetis AE, Barbara R, Frisina R, Farag M, De Salvo G. Functional and structural characteristics in patients with type 3 macular neovascularisation treated with anti-VEGF. Three-year results in real world settings. Eye (Basingstoke). 2024;38(8):1438\u201343. https:\/\/doi.org\/10.1038\/s41433-023-02918-w.","journal-title":"Eye (Basingstoke)"},{"key":"1453_CR18","doi-asserted-by":"publisher","DOI":"10.1111\/ceo.14589","author":"A Hunt","year":"2025","unstructured":"Hunt A, Hashimoto Y, Young S, et\u00a0al. Outcomes after switching to faricimab in neovascular age-related macular degeneration: data from the Fight Retinal Blindness! Registry. Clin Exp Ophthalmol. 2025. https:\/\/doi.org\/10.1111\/ceo.14589. (Published online 2025).","journal-title":"Clin Exp Ophthalmol"}],"container-title":["Ophthalmology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-026-01453-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40123-026-01453-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-026-01453-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T02:03:40Z","timestamp":1785463420000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40123-026-01453-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,6]]},"references-count":18,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["1453"],"URL":"https:\/\/doi.org\/10.1007\/s40123-026-01453-7","relation":{},"ISSN":["2193-8245","2193-6528"],"issn-type":[{"value":"2193-8245","type":"print"},{"value":"2193-6528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,6]]},"assertion":[{"value":"27 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and\/or publication of this article. Federico Beretta, Giovanni Scalabrin, Edoardo Balduzzi, and Stefano Puligheddu declare that they have no competing interests. Riccardo Sacconi is a consultant for AbbVie (North Chicago, Illinois, USA), Bayer Shering-Pharma (Berlin, Germany), Carl Zeiss Meditec (Dublin, USA), Hoffmann-La-Roche (Basel, Switzerland), and Novartis (Basel, Switzerland). Francesco Bandello is a consultant for AbbVie (North Chicago, Illinois, USA), Alcon (Fort Worth,Texas,USA), Alimera Sciences (Alpharetta, Georgia, USA), Farmila-Thea (Clermont-Ferrand, France), Bayer Shering-Pharma (Berlin, Germany), Bausch And Lomb (Rochester, New York, USA), Genentech (San Francisco, California, USA), Hoffmann-La-Roche (Basel, Switzerland), NovagaliPharma (\u00c9vry, France), Novartis (Basel, Switzerland), Sanofi-Aventis (Paris, France), Thrombogenics (Heverlee,Belgium), and Zeiss (Dublin, USA). Giuseppe Querques is a consultant for AbbVie (North Chicago, Illinois, USA), Alimera Sciences (Alpharetta, Georgia, USA), Amgen (Thousand Oaks, USA), Heidelberg (Germany), KBH (Chengdu, China), LEH Pharma (London, UK), Lumithera (Poulsbo, USA), Novartis (Basel, Switzerland), Bayer Shering-Pharma (Berlin, Germany), Sandoz (Berlin, Germany), Sifi (Catania, Italy), Soof-Fidia (Albano, Italy), and Zeiss (Dublin, USA). Giuseppe Querques is an editorial board member of\n                      Ophthalmology and Therapy\n                      . Giuseppe Querques was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures complied with the principles of the Declaration of Helsinki (1964). Formal approval from the local ethics committee was not required, as the study was retrospective in nature and all procedures had already been performed as part of standard clinical care. Since no additional interventions were carried out and the data were anonymized, informed consent was waived in accordance with local regulations.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}